154748-63-7

Usage

Uses

Used in Pharmaceutical Synthesis:
Carbamic acid, (3-hydroxycyclobutyl)-, 1,1-dimethylethyl ester (9CI) is used as an intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs. Its unique structure allows it to be a valuable building block in the creation of complex organic molecules with therapeutic properties.
Used in Agricultural Chemicals:
In the agricultural sector, Carbamic acid, (3-hydroxycyclobutyl)-, 1,1-dimethylethyl ester (9CI) is used as a precursor in the production of certain agricultural chemicals. Its reactivity and structural features make it suitable for the synthesis of compounds that can be used in pest control and crop protection, enhancing agricultural productivity and crop yields.
Used in Medicinal Chemistry Research:
Carbamic acid, (3-hydroxycyclobutyl)-, 1,1-dimethylethyl ester (9CI) is utilized in medicinal chemistry research as a model or probe molecule to study the interactions between biological targets and potential drug candidates. Its cyclobutyl and tert-butyl groups may offer insights into the design of more effective and selective pharmaceutical agents.
Used in Drug Development:
Carbamic acid, (3-hydroxycyclobutyl)-, 1,1-dimethylethyl ester (9CI) is employed in drug development to explore its potential as a lead compound or to improve the pharmacokinetic and pharmacodynamic properties of existing drugs. Its unique structural elements may contribute to the discovery of novel therapeutic agents with improved efficacy and safety profiles.
Note: The specific applications and industries mentioned are inferred from the general context of the compound's potential uses in synthesis and development, as the provided materials do not specify particular applications or industries. Further research and development would be necessary to confirm these uses.

Upstream product

• 389890-43-1 tert-butyl (1,3-cis)-N-(3-hydroxycyclobutyl)carbamate 
• 871014-16-3 trans-3-[(tert-butoxycarbonyl)amino]cyclobutyl 4-nitrobenzoate 
• 130233-77-1 3-oxocyclobutane-1-carbonyl chloride 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 130369-04-9 (3-methylene-cyclobutyl)-carbamic acid tert-butyl ester 
• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 
• 154748-62-6 tert-butyl (3-(benzyloxy)cyclobutyl)carbamate 

Downstream Products

• 1033718-11-4 cis-3-[(tert-butoxycarbonyl)(methyl)amino]cyclobutyl methanesulfonate 
• 1392803-14-3 tert-butyl (trans-3-aminocyclobutyl)methylcarbamate 
• 1284249-30-4 tert-butyl 3-fluorocyclobutylcarbamate 
• 1036260-25-9 3-aminocyclobutan-1-ol hydrogen chloride 
• 154748-62-6 tert-butyl (3-(benzyloxy)cyclobutyl)carbamate 
• 1392804-89-5 tert-butyl ((1r,3r)-3-hydroxycyclobutyl)(methyl)carbamate 
• 1033710-17-6 3-(methylamino)cyclobutanol 
• 1246739-82-1 tert-butyl N-[3-(pyrrolidin-1-yl)cyclobutyl]carbamate 
• 878156-25-3 3-((tert-butoxycarbonyl)amino)cyclobutyl 4-methylbenzenesulfonate 

Relevant academic research and scientific papers

CHEMICAL COMPOUNDS

The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

COMPOUND AS ACC INHIBITOR AND USE THEREOF

Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases.

ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS

The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.

COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY

The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.

DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS

The present disclosure is based, in part, on the discovery that disclosed compounds can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.

COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY

The present disclosure features compounds such as those having the Formulae (Ila), (lIb), (lIc), (Ild), (IlIa), and (Illb), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (Ila), (lIb), (lIc), (lId), (IlIa), or (Illb).

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY

The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.